Sobi to showcase new data across haemophilia portfolio at ISTH 2026

About this update from Swedish Orphan Biovitrum Ab

New analyses and real-world evidence highlight outcomes with Altuvoct®, Elocta® and Alprolix® in haemophilia A and B STOCKHOLM, June 30, 2026 /PRNewswire/ -- Sobi® today announced new data across its haemophilia portfolio will be presented at the 2026 Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Paris, from 11–15 July 2026. Presentations include new analyses and real-world evidence evaluating treatment outcomes with Altuvoct, Elocta and Alprolix in people living with haemophilia A and B. The data being presented include oral and poster presentations evaluating joint health outcomes, bleeding outcomes, perioperative management and real-world treatment experience across multiple patient populations and clinical settings. "People living with haemophilia continue to seek treatment approaches that can support long-term bleed protection, joint health and quality of life in everyday clinical practice," said Lydia Abad-Franch, MD, Chief Medical Officer at Sobi. "The breadth of data being presented at ISTH 2026 reflects our continued commitment to advancing care through both clinical development and real-world evidence generation to help improve outcomes for people living with haemophilia."

View stock analysis, news, and events for Swedish Orphan Biovitrum Ab